Search

everythinglearnresearchcommunity

for

Search:↓

Hormone therapy for excessive hair growth is as good with GnRHa as with high-dose CPA, but GnRHa has longer-lasting results.

Epitestosterone may act as a weak antiandrogen and can inhibit an enzyme involved in testosterone metabolism.

Blocking CYP17A1 enzyme may help improve certain brain function issues related to dopamine.

A compound named ZCZ90 can increase muscle spindle firing, potentially helping treat muscle spasms and hypertension.

Agomelatine may help reduce benign prostatic hyperplasia by blocking certain inflammatory pathways.

The document concludes that a compound with potential for treating prostate cancer and hair loss was successfully made and its detailed structure was confirmed.

PTHRP agonists can stimulate hair growth, especially in damaged follicles, while antagonists may initially increase growth but ultimately inhibit it.

Arachis hypogaea L. root extract reduces prostate enlargement and inflammation in mice.

4-(4-Phenoxybenzoyl)benzoic acid derivatives can both increase and decrease certain types of reactive oxygen species, and may be relevant to hair loss.

DPP4-positive fibroblasts play a major role in producing proteins that lead to skin fibrosis.

ARQ-234, a protein designed to treat atopic dermatitis, shows increased effectiveness in early testing.

Reducing 5α-reductase activity helps endometrial cells differentiate, aiding pregnancy.

A new treatment using a DNA aptamer can promote hair growth by targeting a specific receptor.

A new compound was created in 2010 that can control oil production when applied to the skin, and its effects are completely reversible after two weeks.

Blocking a certain signal in the gp130 receptor can improve tissue healing and lessen osteoarthritis symptoms.

Different substances that activate or block the androgen receptor can affect male development and treat conditions like prostate cancer.

Pfizer found that pantolactam-based compounds can reduce sebum (skin oil) production when applied topically.

A compound from Calophyllum inophyllum L. leaf may help treat non-small cell lung cancer.

FCE 28260 is a stronger and longer-lasting inhibitor of 5α-reductase than finasteride, which may make it a better treatment for certain medical conditions.

Enobosarm may effectively treat androgen receptor-positive breast cancer with fewer side effects.

Eplerenone, a mineralocorticoid receptor antagonist, was found to promote hair growth in human hair follicles.

Precise objectives can improve student achievement in health education.

4-azasteroids, including finasteride, can inhibit 5α-reductase, helping treat conditions like enlarged prostate and hair loss.

Epiregulin can help hair grow and may be useful for treating hair loss.

SIG-1451 could be a promising new treatment for atopic dermatitis.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

Vepdegestrant may become the first FDA-approved PROTAC degrader, marking a new era in drug development.

Ebastine may promote hair regrowth by increasing cell growth through the ERK pathway.

HA-P5 effectively treats acne without causing side effects seen in other treatments.

Docetaxel slightly extends prostate cancer survival but has significant side effects and high cost.